2.07 USD
+0.02 (+0.98%)
2.05 USD
-0.02 (-0.97%)
PLX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here. PLX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year PLX was profitable.
- PLX had a negative operating cash flow in the past year.
- In multiple years PLX reported negative net income over the last 5 years.
- PLX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- PLX's Return On Assets of 8.00% is amongst the best of the industry. PLX outperforms 93.33% of its industry peers.
- PLX has a Return On Equity of 12.57%. This is amongst the best in the industry. PLX outperforms 93.71% of its industry peers.
- PLX has a better Return On Invested Capital (12.68%) than 95.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROIC | 12.68% |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 10.13%, PLX belongs to the top of the industry, outperforming 91.24% of the companies in the same industry.
- With an excellent Operating Margin value of 13.28%, PLX belongs to the best of the industry, outperforming 92.76% of the companies in the same industry.
- PLX has a better Gross Margin (57.53%) than 77.90% of its industry peers.
- In the last couple of years the Gross Margin of PLX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PLX is still creating some value.
- The number of shares outstanding for PLX has been increased compared to 1 year ago.
- PLX has more shares outstanding than it did 5 years ago.
- PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- PLX has an Altman-Z score of -1.55. This is a bad value and indicates that PLX is not financially healthy and even has some risk of bankruptcy.
- PLX has a Altman-Z score (-1.55) which is comparable to the rest of the industry.
- PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.55 |
ROIC/WACC1.38
WACC9.21%
2.3 Liquidity
- A Current Ratio of 2.72 indicates that PLX has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 2.72, PLX is doing worse than 68.19% of the companies in the same industry.
- A Quick Ratio of 1.84 indicates that PLX should not have too much problems paying its short term obligations.
- PLX has a worse Quick ratio (1.84) than 76.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 |
3. Growth
3.1 Past
- PLX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 153.85%, which is quite impressive.
- PLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.47%.
- Measured over the past years, PLX shows a decrease in Revenue. The Revenue has been decreasing by -0.48% on average per year.
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
3.2 Future
- PLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 85.63% yearly.
- PLX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.83% yearly.
EPS Next Y-15.83%
EPS Next 2Y142.73%
EPS Next 3Y85.63%
EPS Next 5YN/A
Revenue Next Year12.02%
Revenue Next 2Y14.31%
Revenue Next 3Y8.83%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 29.57, the valuation of PLX can be described as expensive.
- Compared to the rest of the industry, the Price/Earnings ratio of PLX indicates a rather cheap valuation: PLX is cheaper than 93.33% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.32. PLX is around the same levels.
- PLX is valuated reasonably with a Price/Forward Earnings ratio of 11.71.
- Based on the Price/Forward Earnings ratio, PLX is valued cheaper than 97.71% of the companies in the same industry.
- PLX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.30.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.57 | ||
| Fwd PE | 11.71 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PLX indicates a rather cheap valuation: PLX is cheaper than 96.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 12.25 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as PLX's earnings are expected to grow with 85.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y142.73%
EPS Next 3Y85.63%
5. Dividend
5.1 Amount
- PLX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.07
+0.02 (+0.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-16 2026-03-16/bmo
Inst Owners17.52%
Inst Owner Change0.13%
Ins Owners3.54%
Ins Owner Change0.8%
Market Cap166.47M
Revenue(TTM)53.40M
Net Income(TTM)6.28M
Analysts80
Price Target12.75 (515.94%)
Short Float %5.83%
Short Ratio6.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.51%
Min EPS beat(2)-265.02%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-90.87%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)2
Avg EPS beat(8)-112.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.6%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)14.45%
Revenue beat(4)2
Avg Revenue beat(4)-8.41%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)5
Avg Revenue beat(8)3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-80.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.57 | ||
| Fwd PE | 11.71 | ||
| P/S | 2.69 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.34 | ||
| P/tB | 3.34 | ||
| EV/EBITDA | 12.25 |
EPS(TTM)0.07
EY3.38%
EPS(NY)0.18
Fwd EY8.54%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.77
BVpS0.62
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROCE | 15.12% | ||
| ROIC | 12.68% | ||
| ROICexc | 32.84% | ||
| ROICexgc | 32.84% | ||
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% | ||
| FCFM | N/A |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 91.23% | ||
| Cap/Sales | 2.02% | ||
| Interest Coverage | 10.74 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 | ||
| Altman-Z | -1.55 |
F-Score6
WACC9.21%
ROIC/WACC1.38
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)153.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-15.83%
EPS Next 2Y142.73%
EPS Next 3Y85.63%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%-0.6%
Revenue Next Year12.02%
Revenue Next 2Y14.31%
Revenue Next 3Y8.83%
Revenue Next 5YN/A
EBIT growth 1Y155.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.67%
OCF growth 3YN/A
OCF growth 5YN/A
PROTALIX BIOTHERAPEUTICS INC / PLX FAQ
What is the ChartMill fundamental rating of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
ChartMill assigns a fundamental rating of 4 / 10 to PLX.
Can you provide the valuation status for PROTALIX BIOTHERAPEUTICS INC?
ChartMill assigns a valuation rating of 5 / 10 to PROTALIX BIOTHERAPEUTICS INC (PLX). This can be considered as Fairly Valued.
What is the profitability of PLX stock?
PROTALIX BIOTHERAPEUTICS INC (PLX) has a profitability rating of 5 / 10.
How financially healthy is PROTALIX BIOTHERAPEUTICS INC?
The financial health rating of PROTALIX BIOTHERAPEUTICS INC (PLX) is 5 / 10.